Teclistamab vs Velinotamig (GR1803)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
Teclistamab
Marketed by Johnson & Johnson
NCT05083169 · Phase 3 · active, not recruiting
MajesTEC-3 was a randomized, open-label Phase 3 comparing teclistamab plus daratumumab with daratumumab-based standard regimens (DPd or DVd) in relapsed multiple myeloma. Its primary endpoint, progression-free survival, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (Up to 5 years): Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16). (met)
Result source: NCT05083169
Velinotamig (GR1803)
Developed by Cullinan Therapeutics Inc. under a licence from Genrix Bio
NCT07102706 · Phase 1/2 · completed
The study assigned participants sequentially to different GR1803 doses without randomization, blinding, or a control group. Its primary endpoint was dose-limiting toxicity over 52 weeks, but the registry does not report whether this endpoint was met.
Next expected readout: May 2027 · NCT06566547 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Teclistamab | Velinotamig (GR1803) |
|---|---|---|
| PFS, median | —Trial running · NCT07887984 | —Trial running · NCT07452198 |
| OS, median | —Trial running · NCT07887984 | —Trial running · NCT07452198 |
| ORR | —Trial running · NCT07887984 | —Trial running · NCT07452198 |
| VGPR or better | —Trial running · NCT07887984 | —Trial running · NCT07452198 |
| MRD negativity | —Trial running · NCT07887984 | —Trial running · NCT07452198 |
PFS, median
- Teclistamab
- —Trial running · NCT07887984
- Velinotamig (GR1803)
- —Trial running · NCT07452198
OS, median
- Teclistamab
- —Trial running · NCT07887984
- Velinotamig (GR1803)
- —Trial running · NCT07452198
ORR
- Teclistamab
- —Trial running · NCT07887984
- Velinotamig (GR1803)
- —Trial running · NCT07452198
VGPR or better
- Teclistamab
- —Trial running · NCT07887984
- Velinotamig (GR1803)
- —Trial running · NCT07452198
MRD negativity
- Teclistamab
- —Trial running · NCT07887984
- Velinotamig (GR1803)
- —Trial running · NCT07452198
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Velinotamig (GR1803): no structured comparison results are available for Multiple Myeloma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Teclistamab's landscape · Velinotamig (GR1803)'s landscape